Literature DB >> 2332861

Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins.

K Akashi1, K Nagasawa, T Mayumi, E Yokota, N Oochi, T Kusaba.   

Abstract

Two cases of refractory systemic lupus erythematosus (SLE) were successfully treated with intravenous immunoglobulins (IVIg). In Case 1, the immediate recovery from severe pancytopenia and the improvement of proteinuria were observed, following IVIg therapy in high doses (450 mg/kg) for 5 consecutive days. In Case 2, 3 courses of IVIg therapy (100 mg/kg) for 6 to 8 days resulted in a significant reduction of massive proteinuria. In both cases, the improvement of immunological variables was also seen.

Entities:  

Mesh:

Year:  1990        PMID: 2332861

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

2.  Treatment of a case with pooled intravenous immunoglobulin as an alternative to immunosuppression.

Authors:  F C Hall; R A Watts; L Ginsberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

Review 3.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 5.  Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.

Authors:  S C Jordan; M Toyoda
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

7.  Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations.

Authors:  F Silvestris; P Cafforio; F Dammacco
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin.

Authors:  M J Evans; R Suenaga; N I Abdou
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

9.  Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin.

Authors:  E J ter Borg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

10.  Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients.

Authors:  K Ohkuma; T Sasaki; S Kamei; S Okuda; H Nakano; T Hamamoto; K Fujihara; I Nakashima; T Misu; Y Itoyama
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.